|
Molecular properties generated using the CDK |
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes (source: FDA (1953)) |
IUPAC Name ![]() |
| 1-hydrazinylidene-1,2-dihydrophthalazine |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 1 | hydralazine |
Synonyms ![]() |
| Apresoline® |
Database Links ![]() |
|
| CAS Registry No. | 86-54-4 |
| ChEMBL Ligand | CHEMBL276832 |
| DrugBank Ligand | DB01275 |
| PubChem CID | 3637 |
| RCSB PDB Ligand | HLZ |
| Search Google for chemical match using the InChIKey | RPTUSVTUFVMDQK-UHFFFAOYSA-N |
| Search Google for chemicals with the same backbone | RPTUSVTUFVMDQK |
| Search PubMed clinical trials | hydralazine |
| Search PubMed titles | hydralazine |
| Search PubMed titles/abstracts | hydralazine |
| Wikipedia | Hydralazine |
| Comments |
| Hydralazine is a hydrazinophthalazine class anti-hypertensiove drug. It is on the World Health Organization's List of Essential Medicines (link to 2015 list). |